Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study for Previously Treated Ataluren (PTC124®) Patients With Nonsense Mutation Dystrophinopathy

NCT01557400 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT01557400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01557400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study for Previously Treated Ataluren (PTC124®) Patients With Nonsense Mutation Dystrophinopathy
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 20, 2012
Completion date
January 19, 2018
Enrollment
94 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

becker muscular dystrophy, duchenne muscular dystrophy, dystrophinopathy